A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN) Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Conditions
Lung
Phase I
Volunteers
Health Professionals
What is the purpose of this trial?
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult subjects with KRAS p.G12C mutant advanced solid tumors.
- Trial withAmgen, Inc.
- Start Date01/14/2022
- End Date12/15/2021
For more information about this study, contact:
Kira Fitzsimons Pavlik
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Last Updated01/17/2022
- Study HIC#2000026544